167 related articles for article (PubMed ID: 21831013)
1. Health technology assessments in personalized medicine: illustrations for cost-effectiveness analysis.
Postma MJ; Boersma C; Vandijck D; Vegter S; Le HH; Annemans L
Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):367-9. PubMed ID: 21831013
[No Abstract] [Full Text] [Related]
2. Are current ICER thresholds outdated? Valuing medicines in the era of personalized healthcare.
Carrera P; IJzerman MJ
Expert Rev Pharmacoecon Outcomes Res; 2016 Aug; 16(4):435-7. PubMed ID: 27118144
[No Abstract] [Full Text] [Related]
3. Technology assessment: approach and reimbursement.
Yaszemski MJ; Polly DW; Boden SD; Andersson GB
Spine (Phila Pa 1976); 2007 May; 32(11 Suppl):S39-43. PubMed ID: 17495585
[TBL] [Abstract][Full Text] [Related]
4. Personalized medicine policy challenges: measuring clinical utility at point of care.
van Rooij T; Wilson DM; Marsh S
Expert Rev Pharmacoecon Outcomes Res; 2012 Jun; 12(3):289-95. PubMed ID: 22812553
[TBL] [Abstract][Full Text] [Related]
5. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
6. Early dialogue between the developers of new technologies and pricing and reimbursement agencies: a pilot study.
Backhouse ME; Wonder M; Hornby E; Kilburg A; Drummond M; Mayer FK
Value Health; 2011 Jun; 14(4):608-15. PubMed ID: 21669387
[TBL] [Abstract][Full Text] [Related]
7. Technology assessment for new oncology drugs.
Jönsson B
Clin Cancer Res; 2013 Jan; 19(1):6-11. PubMed ID: 23288370
[TBL] [Abstract][Full Text] [Related]
8. [New EBM: is it really so detrimental to physicians?].
Schmidt K
MMW Fortschr Med; 2004 Sep; 146(39):56-7. PubMed ID: 15532417
[No Abstract] [Full Text] [Related]
9. [Haute Autorite de sante opinion on cost-effectiveness of health products : results and perspectives].
Midy F; Raimond V; Thébaut C; Sambuc C; Rumeau-Pichon C
Sante Publique; 2015; 27(5):691-700. PubMed ID: 26752035
[TBL] [Abstract][Full Text] [Related]
10. Better defining target populations for drugs with a view to reimbursement.
Massol J; Boissel JP
Therapie; 2014; 69(3):235-7. PubMed ID: 24927505
[TBL] [Abstract][Full Text] [Related]
11. The clinical context of technology assessment.
Smits HL
J Health Polit Policy Law; 1984; 9(l):31-40. PubMed ID: 11650667
[TBL] [Abstract][Full Text] [Related]
12. [Economic feasibility study and reimbursement rules--illustrated by a concrete example].
Keiding H; Faergeman O
Ugeskr Laeger; 2008 Feb; 170(8):651-4. PubMed ID: 18364159
[TBL] [Abstract][Full Text] [Related]
13. Regulation, reimbursement, and the long road of implementation of personalized medicine--a perspective from the United States.
Frueh FW
Value Health; 2013; 16(6 Suppl):S27-31. PubMed ID: 24034309
[TBL] [Abstract][Full Text] [Related]
14. Update on technology assessment in dentistry.
Antczak-Bouckoms A; Tulloch JF
Curr Opin Dent; 1992 Jun; 2():10-4. PubMed ID: 1387819
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetics and personalized medicine.
Li-Wan-Po A
J Clin Pharm Ther; 2012 Dec; 37(6):617-9. PubMed ID: 23013532
[No Abstract] [Full Text] [Related]
16. How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach.
Williams I; Bryan S; McIver S
J Health Serv Res Policy; 2007 Apr; 12(2):73-9. PubMed ID: 17407655
[TBL] [Abstract][Full Text] [Related]
17. Technology assessment in medicine: methods, status and trends.
Hendee WR
Med Prog Technol; 1991; 17(2):69-75. PubMed ID: 1835752
[TBL] [Abstract][Full Text] [Related]
18. A survey of reimbursement practices of private health insurance companies for pharmaceuticals not covered under the Pharmaceutical Benefits Scheme 2008.
Lingaratnam SM; Kirsa SW; Mellor JD; Jackson J; Crellin W; Fitzsimons M; Zalcberg JR
Aust Health Rev; 2011 May; 35(2):204-10. PubMed ID: 21612735
[TBL] [Abstract][Full Text] [Related]
19. Medicare and cost-effectiveness analysis.
Neumann PJ; Rosen AB; Weinstein MC
N Engl J Med; 2005 Oct; 353(14):1516-22. PubMed ID: 16207857
[No Abstract] [Full Text] [Related]
20. Response to the expertise: procedures and methods of benefit assessments for medicines in Germany, by Geertruida E. Bekkering and Jos Kleijnen.
Koch K; Lange S
Eur J Health Econ; 2009 May; 10(2):233-6. PubMed ID: 19123011
[No Abstract] [Full Text] [Related]
[Next] [New Search]
